ESMO 2019 Congress | OncologyPRO

Abstract 5139

Background

The prognostic value of the inflammatory indexes (eg. neutrophil-to-lymphocyte ratio, NLR; and systemic immune-inflammation index, SII) was demonstrated among patients with epithelial ovarian cancer (EOC). This study aimed to evaluate their predictive value in terms of platinum-free interval (PFI) as regard to bevacizumab treatment received.

Methods

A total of 375 EOC patients were retrospectively analyzed, 301 treated with chemotherapy alone and 74 with bevacizumab, with the decision to include this drug in the chemotherapy regimen left to the discretion of the treating physician. The correlation between NLR (defined as the ratio of neutrophil to lymphocyte count) and SII, calculated as (platelet count × neutrophil count)/lymphocyte count, and PFI were analyzed using logistic regression analyses adjusted for baseline patient characteristics. Cutoff values were determined using Receiver Operating Characteristic (ROC) analysis.

Results

In univariate analysis, patients with high NLR (≥3) and SII (≥730) had a significantly shorter PFI at 6 and 12 months in overall cohort. In multivariate analysis, only NLR was an independent predictive factor for PFI at 6 months (OR = 2.52, 95% CI 1.30–4.87, p = 0.006) and at 12 months (OR = 2.05, 95% CI 1.05–4.01, p = 0.036) in the overall population and in the chemotherapy group (OR = 2.77, 95% CI 1.38–5.56, p = 0.004; HR = 2.27, 95% CI 1.10–4.70, p = 0.027, respectively). Inflammatory indexes were not predictive for PFI in the bevacizumab group (Table).Table: 1020P

	PFI at 6 months	PFI at 12 months
	N. pts	N. pts	OR (95% CI)	p	N. pts	N. pts	OR (95% CI)	p
NLR
<3	74	139	1.00		113	98	1.00
≥3	80	68	2.52 (1.30-4.87)	0.006	106	37	2.05 (1.05-4.01)	0.036
SII
<730	52	99	1.00		76	73	1.00
≥730	102	108	0.74 (0.36-1.53)	0.413	143	62	0.91 (0.45-1.84)	0.786
CT
NLR
<3	62	115	1.00		98	78	1.00
≥3	69	48	2.77 (1.38-5.56)	0.004	89	24	2.27 (1.10-4.70)	0.027
SII
<730	41	80	1.00		63	56	1.00
≥730	90	83	0.76 (0.35-1.67)	0.498	124	46	0.84 (0.39-1.82)	0.663
CT+B
NLR
<3	12	24	1.00		15	20	1.00
≥3	11	20	0.47 (0.04-5.15)	0.538	17	13	0.75 (0.11-5.25)	0.774
SII
<730	11	19	1.00		13	17	1.00
≥730	12	25	1.65 (0.13-20.56)	0.696	19	16	1.78 (0.21-15.14)	0.599

Conclusions

The NLR was an independent predictive factor for platinum-sensitivity in patients with EOC treated with chemotherapy. Its predictive role seems to be lost in patients treated with bevacizumab.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

MITO group.

Funding

MITO group.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

29 Sep 2019